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Table 1. Patient Demographics
Variable All Patients N549 (100%)
Patient Gender
Female 28 (57.1)
Male 21 (42.9)
Median Age at transplant 57 (19-71)
Disease / Disease status
ALL/CR1 and CR2 9
ALL/Induction failure 1
AML/CR1 and CR2 12
AML/Relapse and Induction failure 7
CML/CP1 and CP2 2
CML/ AP and BC 2
NHL 5
CLL 1
MDS 8
MPN 2
Conditioning Regimen
Reduced Intensity Fludarabine/
Melphalan
31
FTBI/Cytoxan 7
FTBI/VP-1611 11
HLA Match
10 out of 10 26
others 23
ALL; Acute Lymphoblastic Leukemia, CR; Complete Remission, CP;
Chronic Phase, AP;Accelrated Phase, BC;Blast Crisis, NHL; Non-Hodg-
kin Lymphoma, CLL;Chronic lymphocytic leukemia, MDS;Myelodysplas-
tic Syndromes, MPN; Myeloproliferative Neoplasm
S330 Poster Session IIbetter elucidate this, our group is conducting a prospective study that
evaluates the T cell receptor (TcR) Vb repertoire from patients who
are undergoing either matched related (MRD) or unrelated (URD)
donor allogeneic hematopoietic stem cell transplantation (HSCT)
for treatment of hematologic malignancies. These patients received
conditioning therapy with a regimen combining rabbit anti-thymo-
cyte globulin (Thymoglobulin, Genzyme, Cambridge, MA) and
450 cGy total body irradiation. We used a novel two-tier analysis
of TcR Vb mRNA expression in order to identify GVHD and/or
GVT-associated T cell clones: i) normalization of the TcR Vb
mRNA to CD3 mRNA rather than to housekeeping genes using
real-timeRT-PCRwhich increases sensitivity of the assay for detect-
ing minimal circulating T cell clones of interest that are activated;
ii) comparative analysis of the recipients’ TcR Vb over those of the
donors’ at the time of GVHD or GVT effects up to 1 year post-
HSCT. We then performed spectratyping analysis to confirm clon-
ality of the relevant T cell clones. We have been able to identify
T cell populations in the HSCT recipients at 90 days to 1 year fol-
lowing transplant, by demonstrating that distinct TcRVb transcripts
were significantly increased relative to the steady state expression in
the donor, in patients without GVHD or relapse vs. patients with
GVHD. In the three GVHD-free, relapse-free patients, we found
an increased expression of Vb 9 in all patients as well as an increased
expression of Vb 16 and Vb5/Vb 24 in two and one patient, respec-
tively. In 6 patients with GVHD, we observed increased expressions
of Vb4 and Vb11 in four patients and increased Vb23 in three
patients. Spectratyping analyses of each of these TcR Vb families
showed distinct skewed, mono- or oligoclonal populations, in pa-
tients with GVHD or GVHD- and relapse-free states. The identifi-
cation of these unique T cell clones in patients who have developed
GVHD or GVHD-free responses after allogeneic HSCT suggests
that they may be driven by antigen stimulation uniquely associated
with GVHD or GVT. Identification of GVHD-associated T cell
clones may offer aan opportunity for targeted therapy of GVHD
rather than using conventional immunosuppressive drugs.492
SIROLIMUS, TACROLIMUS, AND RABBIT ATG (R-ATG) AS GRAFT-VERSUS-
HOST DISEASE PROPHYLAXIS IN PATIENTS UNDERGOING UNRELATED
DONOR PERIPHERAL BLOOD HEMATOPOIETIC CELL TRANSPLANT
(HCT): EXTENDED FOLLOW UP AND UPDATED ANALYSIS
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L., Pullarkat, V., Senitzer, D., Forman, S., Nakamura, R. City of Hope,
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The combined use of Sirolimus (SIR) and Tacrolimus (FK) +/2
low-dose methotrexate (MTX) recently showed a promising result
in preventing acute GVHD after unrelated donor HCT (Antin et
al. Blood 2003) although a significant number of patients still expe-
rienced chronic GVHD. In an attempt to further improve the out-
come, we have evaluated a novel combination of Tacrolimus,
Sirolimus and r-ATG (4.5 mg/kg) +/2 Methotrexate (for patients
with a mismatched donor). We have previously presented the early
results of this combination. In this report we extended the follow-
up period and updated analysis focused on 49 patients who received
PBSCT (See Table 1 for patient demographics).
Results:Engraftment rate was 91.8% (n5 45) with the median neu-
trophil engaftment at 15 days (range: 10-39). Seventeen patients
(38% of 45 engrafted) developed grade II-IV acute GVHD (grade
III 5 3, IV 5 0). Chronic GVHD developed in 23 of 38 evaluable
patients (60%, limited n 5 4, extensive n 5 19). We observed
TTP/HUS in 10 patients (20%) and one case of VOD. Eighteen
(42%) of 43 patients at risk (Recipient +ve or Donor +ve) developed
CMV reactivation, while 10 patients developed EBV reactivation
(19.6%). After a median follow up of 24 months (range: 6-48) for
33 surviving patients, the 1-year OS, DFS, and relapse rate were
75.4% (95%CI: 64.8-83.2), 73.4% (63.0-81.3), and 8.2%
(3.2-21.0), respectively. Non-relapse mortality (NRM) was 16.3%
(8.7-30.8) at 100 day and 18.4% (10.2-33.2) at 1 year. There were
no significant differences in the outcomes according to conditioning
regimens, although there was a trend for lower NRM with Flu/Mel
(9.7% vs. 27.8% at 1 year, p 5 0.06).
In summary the combination of FK/SIR with r-ATG +/2MTX
may improve the GVHD and survival outcome in this high-risk pop-ulation. However, we observed graft failure in 4 patients, which ap-
peared to be a higher rate than our historic data of approximately 2%
in the setting of unrelated donor HCT.493
NRF2 REGULATES ALLOREACTIVE T CELL FUNCTION DURING GVHD
Tsai, J.J.1, Tran, H.1, Smith, O.M.1, Yim, N.1, Rao, U.1, Takahashi, K.1,
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The activation and regulation of donor alloreactive T cells is crit-
ical for the development of graft-versus-host disease (GVHD) as well
as the regulation of graft-versus-tumor (GVT) activity. To better
understand transcriptional orchestration of alloreactive T cells, we
employed Finding Informative Regulatory Elements (FIRE)
approach, recently published by Elemento et al, to investigate gene
expression data in donor T cells in murine syngeneic (syn-) and allo-
geneic bone marrow transplant (allo-BMT) models. We discovered
the presence and absence of the motif CCGGAAG, recognized by
the transcription factor Nuclear Factor Erythroid 2-Like Factor 2
(Nrf-2), correlated to a set of genes that were slightly upregulated
in syn- and downregulated in allo-donor T cells. We hypothesized
that Nrf-2 serves as a master regulator of genes in alloreactive donor
T cells involved in the GVHD setting.
We first examined the level of expression of Nrf-2 in donor T cells
in murine syn- and allo-BMTmodels. We found that the expression
of Nrf-2 was significantly reduced only in the regulatory T cell pop-
ulation (CD4+CD25+Foxp3+) in allo-BMT (p 5 0.0004). We next
questioned the significance of Nrf-2 in alloreactive T cells. Adoptive
transfer of Nrf2-/- donor T cells leads to less GVHD morbidity, as
characterized by weight loss (p\ 0.0001) and better survival (p 5
0.0030), compared to Nrf-2+/+ donor T cells. Interestingly, loss of
functional Nrf-2 in donor T cells did not perturb their GVT activity
at the studied dose (A20, 0.25x106 per host). We demonstrated that
CFSE labeledNrf2-/- donor T cells have intact proliferation and ac-
tivation (as determined by the upregulation of CD25) upon stimula-
tion by alloantigen. Lastly, we investigated the trafficking ability of
Nrf2-/- donor T cells to gut-associated lymphoid tissues. Although
not statistically significant, there were less Nrf2-/- donor T cells in-
filtrating the mesenteric lymph nodes (MLNs) compared to Nrf2+/+
